-

Eurofins CDMO Alphora Inc. Announces the Launch of Expanded Drug Product Analytical Laboratory

MISSISSAUGA, Canada--(BUSINESS WIRE)--Eurofins CDMO Alphora Inc., a global Contract Development & Manufacturing Organization and part of the international network of Eurofins laboratories, is pleased to announce a significant expansion of its Drug Product Analytical Services Laboratory, increasing its footprint three-fold. Located in Mississauga, Canada, the expanded facility marks the addition of specialized equipment and analytical techniques, tailored to offer comprehensive analytical support for drug product programs. The laboratory has expanded to encompass water activity measurements, intrinsic dissolution studies, additional glove box systems, an added suite of HPLCs, new stability chambers and gas chromatography.

Eurofins CDMO Alphora Inc is committed to supporting the development and manufacturing of life-saving therapies and providing the highest standards of quality, customized support, and expert analysis to its clients. Through the Drug Product Analytical Services Laboratory expansion and Eurofins CDMO Alphora Inc’s drug product capabilities and extensive suite of Solid-State Research and Development, Eurofins CDMO Alphora is well positioned to support even the most challenging drug development programs.

To learn more, please visit:
https://www.eurofins.com/biopharma-services/cdmo/services/small-molecules-dp-development-manufacturing/

About Eurofins CDMO Alphora Inc.
Eurofins CDMO is a leading global Contract Development and Manufacturing Organization that provides clients with active pharmaceutical ingredients (“API’s”) / drug substance and drug product development for small molecules, biologics and phytocannabinoids via synthetic route. Its service offering encompasses drug substance/API development, solid state research and development, pre-formulation, formulation and development, analytical development, Non-GMP & GMP manufacturing, upstream development, downstream development, ADC Conjugation. Operating with facilities in Europe, North America and India, Eurofins CDMO is accredited through the FDA, EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With ca. 62,000 staff across a network of more than 900 laboratories in over 1,000 companies in 62 countries, Eurofins offers a portfolio of over 200,000 analytical methods.
Eurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.

Contacts

For further information:
Cheryl Young
Senior Vice President Business Operations
Eurofins CDMO Alphora Inc.
Cheryl.Young@bpt.eurofinsca.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

For further information:
Cheryl Young
Senior Vice President Business Operations
Eurofins CDMO Alphora Inc.
Cheryl.Young@bpt.eurofinsca.com

More News From Eurofins

Eurofins Scientific SE: Weekly Report on Share Repurchases from 23rd April to 24th April 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 40 000 61.8744 XPAR EUROFINS SCIENTIFC 529900JEHFM47DYY3S57 23/04/2026 FR0014000MR3 10 000 61.9124 CEUX EUROFINS SCIENTIFC 529900JEHFM47D...

Eurofins Launches Seventh Buy-Back Programme of Its Own Shares

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (the “Company”) (EUFI.PA) (Paris:ERF) announces its intention to launch a new buy-back programme of its own shares (ISIN FR0014000MR3) for a maximum amount representing up to 4.5% of its share capital. The maximum amount meant for the repurchase of the Company’s shares may not exceed a sum corresponding to an amount equivalent to the value of 4.5% of the shares composing the share capital of the Company as of the Board of Dire...

Eurofins Achieves Organic Growth of 2.6% in Q1 2026, Including Impact of Exceptionally Severe Weather; 2026 and Mid-Term Objectives Reiterated

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: The Eurofins (Paris:ERF) network of companies delivered steady growth despite significant temporary headwinds: Reported revenues in Q1 2026 totalled €1,789m, an increase of 1.3% vs Q1 2025. This was driven by both organic growth13 and acquisitions, with a -4.8% headwind from foreign exchange as the Euro strengthened against most currencies compared to the prior year quarter. Organic revenue growth13 in Q1 2026 was 2.6%, which includes a +0.1% adjust...
Back to Newsroom